ImmunoPET in Multiple Myeloma—What? So What? Now What?

Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (includi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailly, Clément, Chalopin, Benjamin, Gouard, Sébastien, Carlier, Thomas, Remaud-Le Saëc, Patricia, Marionneau-Lambot, Séverine, Moreau, Philippe, Touzeau, Cyrille, Kraeber-Bodere, Françoise, Bodet-Milin, Caroline, Chérel, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352991/
https://www.ncbi.nlm.nih.gov/pubmed/32512883
http://dx.doi.org/10.3390/cancers12061467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352991/
https://www.ncbi.nlm.nih.gov/pubmed/32512883
http://dx.doi.org/10.3390/cancers12061467

Ejemplares similares